ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Research on Treatment of Psoriasis by Human Umbilical Cord-derived Mesenchymal Stem Cells

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03765957
Recruitment Status : Not yet recruiting
First Posted : December 5, 2018
Last Update Posted : December 5, 2018
Sponsor:
Information provided by (Responsible Party):
Yijing He, Central South University

Brief Summary:
To evaluate the effect and safety of treatment of psoriasis by human umbilical cord blood-derived mesenchymal stem cell

Condition or disease Intervention/treatment Phase
Psoriasis Biological: Mesenchymal Stem Cells Drug: Oral Methotrexate Early Phase 1

Detailed Description:

Psoriasis is a chronic and recurrent inflammatory skin disease and its histological features are characterized by epidermal hyperplasia, increased angiogenesis and immune cell infiltration. Psoriasis prevalence is about 0.1%-3%, affecting approximately 125 million people worldwide. In China, there are about 10 million psoriasis patients.

Human umbilical cord blood-derived MSC (hUCB-MSC) has many advantages for the treatment of immune disease. Because it was demonstrated that hUCB-MSCs are effective in modulating immune cells and treating diseases and it has low immunogenicity. Furthermore, hUCB-MSCs do not raise ethical issue for clinical applications.

Some experimental results and cases has showed that mesenchymal stem cell (MSC) can prevent or treat psoriasis. This clinical study is conducted to provide more data to evaluate the effect and safety of treatment of psoriasis by human umbilical cord blood-derived mesenchymal stem cell.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Research on Treatment of Psoriasis by Human Umbilical Cord-derived Mesenchymal Stem Cells
Estimated Study Start Date : January 1, 2019
Estimated Primary Completion Date : July 31, 2020
Estimated Study Completion Date : June 1, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: Mesenchymal Stem Cells
The mesenchymal stem cells will be derived from human umbilical cord. The subjects will be injected intravenously with 1x10E6/kg (according to the weight of subject)mesenchymal stem cells at baseline and every 2 weeks until week 6.
Biological: Mesenchymal Stem Cells
The subjects will be injected intravenously with 1x10E6/kg (according to the weight of subject)Human Umbilical Cord-derived Mesenchymal Stem Cells at baseline and every 2 weeks until week 6. Besides MSC, conventional moisturizer such 10% boric acid ointment is given to all patients in the treatment and follow-up period.
Other Name: Human Umbilical Cord-derived Mesenchymal Stem Cells

Active Comparator: Oral Methotrexate
The subjects will be treated with oral methotrexate 7.5-15mg every week (The dose will start from 7.5mg/w and increase to 15mg/w depending on the response of subjects). This is a conventional systemic treatment.
Drug: Oral Methotrexate
The subjects will be treated with oral methotrexate 7.5-15mg every week (The dose will start from 7.5mg/w and increase to 15mg/w depending on the response of subjects). Besides methotrexate, conventional moisturizer such 10% boric acid ointment is given to all patients in the treatment and follow-up period.
Other Name: MTX




Primary Outcome Measures :
  1. Number of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement [ Time Frame: Month 6 ]
    The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 was defined as having an improvement of at least 75% in the PASI scores compared to baseline.

  2. Number of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) [ Time Frame: Month 6 ]
    The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1.


Secondary Outcome Measures :
  1. Number of Participants Achieving an sPGA (0) [ Time Frame: Month 6 ]
    The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0) response was defined as a post-baseline sPGA score of 0.

  2. Number of Participants Achieving ≥90% (PASI 90) Improvement [ Time Frame: Month 6 ]
    The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 90 were defined as having an improvement of at least 90% in the PASI scores compared to baseline.

  3. Number of Participants Achieving 100% [ Time Frame: Month 6 ]
    The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.

  4. Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score [ Time Frame: Baseline, Month 6 ]
    The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant. Least Square (LS) Means in total DLQI score were calculated using Mixed Model Repeated Measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosed according to Classification criteria for Psoriasis vulgaris for more than 6 months;
  2. Body Mass Index (BMI) between 18.5-35;
  3. Resistance to phototherapy, systemic therapy, or a combination of these therapies
  4. BSA(body surface area)>10%, sPGA>3 and PASI>10 at baseline;
  5. Understanding the whole process of the study, voluntary participation and signed the informed consent.

Exclusion Criteria:

  1. WBC(white blood cell count ) <3.0x109/L, blood platelet count<100x109/L, hemoglobin<100g/L serum creatinine>1.5 x ULN(upper limit of normal), bilirubin > 1.5 x ULN(upper limit of normal), AST(SGOT,glutamic-oxalacetic transaminase)/ALT(SGPT,glutamic-pyruvic transaminase) >2.5 x ULN(upper limit of normal);
  2. Pregnant women, or women who ready for pregnancy or lactating;
  3. Have a serious heart, lung, kidney and other vital organs and endocrine system lesions and the history;
  4. Patients suffering from malignant tumor;
  5. Patients suffering from any acute or chronic infectious diseases;
  6. Mental disorders, history of alcohol abuse, drug or other substance abuse;
  7. Patients participated in any clinical trials within 3 months or any stem cell therapy within 6 months;
  8. Having a serious allergic history or being allergic to two or more than 2 kinds of food or drugs;
  9. Patients who have received systemic therapy within recent one month or topical therapy in two weeks;
  10. Either HIV-antibody(human immunodeficiency virus-antibody), HBV-antibody (hepatitis B virus-antibody ) or syphilis antibody is positive;
  11. Other cases which researchers believe that can not enroll.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03765957


Contacts
Contact: Mi Zhang 08615116331788 ext 08615116331788 648979182@qq.com

Sponsors and Collaborators
Central South University

Publications:

Responsible Party: Yijing He, Associate professor, Central South University
ClinicalTrials.gov Identifier: NCT03765957     History of Changes
Other Study ID Numbers: 2018-MSC/CSU/PS
First Posted: December 5, 2018    Key Record Dates
Last Update Posted: December 5, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Yijing He, Central South University:
Mesenchymal Stem Cells

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Methotrexate
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors